Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mezei

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 5, 2020
A National Spinal Muscular Atrophy Registry for Real-World EvidenceVictoria L Hodgkinson, Maryam Oskoui, Joshua Lounsberry, et al.
JAMA Neurology|February 3, 2015
A genome-wide association study of myasthenia gravisAlan E Renton, Hannah A Pliner, Carlo Provenzano, et al.
Journal of Neuromuscular Diseases|September 14, 2020
The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease RegistryV Hodgkinson, J Lounsberry, S M'Dahoma, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
BMJ Open|September 19, 2020
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North AmericaJoshua D Green, Richard J Barohn, Emanuela Bartoccion, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 5, 2020
A National Spinal Muscular Atrophy Registry for Real-World EvidenceVictoria L Hodgkinson, Maryam Oskoui, Joshua Lounsberry, et al.
JAMA Neurology|February 3, 2015
A genome-wide association study of myasthenia gravisAlan E Renton, Hannah A Pliner, Carlo Provenzano, et al.
Journal of Neuromuscular Diseases|September 14, 2020
The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease RegistryV Hodgkinson, J Lounsberry, S M'Dahoma, et al.
Pageof 10